摘要 |
<p>The invention provides a pharmaceutical product, kit or composition comprising a first active ingredient which is N-[2-(Diethylamino)ethyl]-N-(2-{[2-(4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl)ethyl]amino}ethyl)-3-[2-(3-chlorophenyl)ethoxy]pro panamide or a salt thereof, and a second active ingredient selected from: a non-steroidal Glucocorticoid Receptor (GR Receptor) Agonist; an antioxidant; a CCR1 antagonist; a chemokine antagonist (not CCR1); a corticosteroid; a CRTh2 antagonist; a DP1 antagonist; an Histone Deacetylase Inducer; an IKK2 inhibitor; a COX inhibitor; a lipoxygenase inhibitor; a leukotriene receptor antagonist; an MPO inhibitor; a muscarinic antagonist; a p38 inhibitor; a PDE inhibitor; a PPAR? agonist; a protease inhibitor; a Statin; a thromboxane antagonist; a vasodilator; or, an ENAC blocker (Epithelial Sodium-channel blocker); and its use in the treatment of respiratory disease.</p> |
申请人 |
ASTRAZENECA AB;ASTRAZENECA UK LIMITED;CADOGAN, ELAINE, BRIDGET;CONNOLLY, STEPHEN;NICHOLLS, DAVID, JOHN;WILEY, KATHERINE, ELISABETH;YOUNG, ALAN |
发明人 |
CADOGAN, ELAINE, BRIDGET;CONNOLLY, STEPHEN;NICHOLLS, DAVID, JOHN;WILEY, KATHERINE, ELISABETH;YOUNG, ALAN |